Active material: Molsidomin
When ATH: C01DX12
CCF: Peripheral vasodilators. Antianginal drug
When CSF: 01.06.01.02
Manufacturer: Aventis Pharma Germany GmbH (Germany)
Pills white or nearly white, oblong, lenticular, с двух сторон гравировка “MFG” и стилизованная буква “h”, risk-sharing.
| 1 tab. | |
| molsidomin | 4 mg |
[Ring] lactose monohydrate, krospovydon, macrogol 6000, magnesium stearate.
10 PC. – блистеры (3) – пачки картонные.
Antianginal drugs from the group sydnonimine. Action molsidomine realized by formed during its metabolism of nitric oxide (NO), which stimulates the soluble guanylate cyclase. As a result, there is an accumulation of cGMP, which relaxes smooth muscle walls of blood vessels. Molsidomine causes a decrease in venous pressure, end-diastolic pressure in the ventricle and pulmonary artery pressure. Lowers myocardial oxygen demand. Extends the major coronary arteries, improves the collateral circulation in coronary atherosclerosis. In chronic heart failure under the influence of molsidomine reduced ventricular dilatation.
After oral administration, molsidomine is almost completely (90%) absorbed from the gastrointestinal tract. Eating does not affect the extent and rate of absorption. Binding to plasma proteins is approximately 10%.
It is metabolized in the liver with the formation of active metabolites (mainly lipsidomina, ie. SIN-I A, releasing NO), which are then inactivated. Molsidomine and its metabolites are primarily excreted in the urine (90%).
T1/2 increases with abnormal liver function.
Prevention of angina attacks (orally); relief of angina attacks (sublingual application).
Individual. Single dose 1-4 mg, the multiplicity of reception 2-3 times / day.
Cardio-vascular system: at the beginning of treatment may be headache (stops during therapy); редко – покраснение лица, orthostatic hypertension.
Co of the digestive system: nausea, diarrhea, loss of appetite.
Cardiogenic shock, severe hypotension, reduction in central venous pressure, glaucoma, Hypersensitivity to molsidomin.
Pregnancy is possible only in cases, when the expected benefit of therapy for the mother outweighs the potential risk to the fetus.
If necessary, use during lactation should decide the issue of termination of breastfeeding.
With extreme caution in patients with recent myocardial infarction. Elderly patients with impaired hepatic or renal function and arterial hypotension dose adjustment is required.
Effects on ability to drive vehicles and management mechanisms
During the period of molsidomine (especially at the beginning of treatment) It should refrain from activities potentially hazardous activities, requiring increased attention and rapid psychomotor reactions.
At simultaneous application with antihypertensive, vasodilators may increase antihypertensive action.
In an application with acetylsalicylic acid increases the antiplatelet effect of aspirin.
While the use of ethanol increases the risk of hypotension.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More